Highlights Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

Market Closed - Nasdaq Other stock markets 16:30:00 2024-06-07 EDT			5-day change	1st Jan Change
1.85 ^USD	-0.26%		-1.06%	-25.70%

05-08	Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	CI
05-08	Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review	05-08	CI
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November	05-07	MT
Alterity Therapeutics Limited Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Diseases	04-29	CI
ADRs End Lower, Purple Biotech Ltd. Declines 29%	04-16	DJ
ADRs End Higher, Lixiang Education Holding Co. Ltd. Climbs 69%	04-11	DJ
ADRs Close Lower; VIA Optronics AG Declines 30%	04-10	DJ
Top Midday Gainers	04-10	MT
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund	03-25	MT
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-29	CI
Alterity Therapeutics Limited Reports Earnings Results for the Half Year Ended December 30, 2023	02-28	CI
Alterity Therapeutics's Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Second Review	02-06	CI
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease	12-04	CI
Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy	11-27	CI
Alterity Therapeutics Completes Enrolment in Ath434-201 Phase 2 Clinical Trial in Multiple System Atrophy	11-08	CI
Alterity Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Alterity Therapeutics Says it Secured European Patent Covering Neurodegenerative Disease Drug Candidates	23-08-23	MT
Alterity Therapeutics Limited Grants New Composition of Matter Patent in Europe for Neurodegenerative Diseases Including Parkinson's and Alzheimer's	23-08-23	CI
Alterity Therapeutics Limited Announces an Independent Data Monitoring Committee Recommends the ATH434-201 Phase 2 Study	23-07-26	CI
Alterity Therapeutics Initiates Second Phase 2 Study in Rare Parkinsonian Disorder	23-05-30	CI
Alterity Therapeutics Enrolls First Patient in Australia in Ath434 Global Phase 2 Clinical Trial in Multiple System Atrophy	23-05-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Alterity Therapeutics Limited Nasdaq

Equities

ATHE

US02155X2053

Highlights

Filters